Intradermal delivery for vaccine dose sparing: Overview of current issues

Vaccine

Volumn 31, Issue 34, 2013, Pages 3392-3395

  Zehrung, Darin ^a   Jarrahian, Courtney ^a   Wales, Amy ^a  

^a PATH   (United States)

Author keywords

Delivery devices; Dose sparing; Intradermal delivery; Reduced dose vaccination; Vaccine delivery

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; PRESERVATIVE; RABIES VACCINE; TETANUS TOXOID; TICK BORNE ENCEPHALITIS VACCINE; VACCINE; YELLOW FEVER VACCINE;

ARTICLE; CLINICAL EFFECTIVENESS; COST CONTROL; DISPOSABLE EQUIPMENT; DRUG APPROVAL; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MANUFACTURE; FREEZE DRYING; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; JET INJECTOR; LIQUID; LOWEST INCOME GROUP; MASS IMMUNIZATION; MICRONEEDLE; OPTIMAL DRUG DOSE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SYRINGE; SYRINGE NEEDLE;

DELIVERY DEVICES; DOSE SPARING; INTRADERMAL DELIVERY; REDUCED-DOSE VACCINATION; VACCINE DELIVERY;

HUMANS; INJECTIONS, INTRADERMAL; NEEDLES; VACCINATION; VACCINES;

EID: 84880512667     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.021     Document Type: Article

References (31)

1. Nestle F.O., Di Meglio P., Qin J.Z., Nickoloff B.J. Skin immune sentinels in health and diseases. Nat Rev Immunol 2009, 9(10):679-691.
2. Hickling J.K., Jones K.R., Friede M., Zehrung D., Chen D., Kristensen D. Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ 2011, 89:221-226.
3. Nelson K.S., Janssen J.M., Troy S.B., Maldonado Y. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine 2012, 30(2):121-125.
4. Icardi G., Orsi A., Ceravolo A., Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system. Hum Vaccin Immunother 2012, 8(1):67-75.
5. Hickling J., Jones R., PATH, World Health Organization Intradermal delivery of vaccines: a review of the literature and the potential for development for use in low- and middle-income countries 2009, PATH, Seattle, Available at:. http://www.path.org/publications/detail.php%3Fi=1746.
6. Mohammed A.J., AlAwaidy S., Bawikar S., Kurup P.J., Elamin E., Shaban M.M., et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010, 362(25):2351-2359.
7. Cadorna-Carlos J., Vidor E., Bonnet M.C. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis 2012, 16(2):e110-e116.
8. Roukens A.H., Vossen A.C., Bredenbeek P.J., van Dissel J.T., Visser L.G. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One 2008, 3(4):e1993.
9. Roukens A.H., Vossen A.C., van Dissel J.T., Visser L.G. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine 2009, 27(18):2408-2409.
10. Wilck M.B., Seaman M.S., Baden L.R., Walsh S.R., Grandpre L.E., Devoy C., et al. Safety and immunogenicity of modified vaccine Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 2010, 201(9):1361-1370.
11. Arnou R., Eavis P., Pardo J.R., Ambrozaitis A., Kazek M.P., Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: randomized, controlled, phase III trial. Hum Vaccin 2010, 6(4):346-354.
12. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27(3):454-459.
13. Belshe R.B., Newman F.K., Wilkins K., Graham I.L., Babusis E., Ewell M., et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007, 25(37-38):6755-6763.
14. Fishbein D.B., Pacer R.E., Holmes D.F., Ley A.B., Yager P., Tong T.C. Rabies preexposure prophylaxis with human diploid cell rabies vaccine: a dose-response study. J Infect Dis 1987, 156(1):50-55.
15. Warrell M.J., Nicholson K.G., Warrell D.A., Suntharasamai P., Chanthavanich P., Viravan C., et al. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985, 1(8437):1059-1062.
16. Quimbao B.P., Dimaano E.M., Ambas C., Davis R., Banzhoff A., Malerczyk C. Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 2005, 23(14):1709-1714.
17. Sanofi Aventis Safety and immunogenicity of intradermal versus subcutaneous doses of menomune 2010, Sanofi Pasteur Inc., Available at:. http://clinicaltrials.gov/ct2/show/results/NCT00850603.
18. Khawplod P., Wilde H., Sirikwin S., Benjawonqkulchai M., Limusanno S., Jaijaroensab W., et al. Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine 2006, 24(16):3084-3086.
19. World Health Organization Rabies vaccines. WHO position paper. Wkly Epidemiol Rec 2010, 85:309-320.
20. Weniger B.G., Papania M.J. Alternative vaccine delivery methods. Vaccines 2013, 1200-1231. Elsevier/Saunders, Philadelphia, [chapter 61]. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
21. PATH, Working in Tandem Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries: an economic analysis of strategies to reduce the cost of routine IPV immunization 2010, Seattle, PATH, Available at:. http://www.path.org/publications/detail.php%3Fi=1809.
22. Griffiths U.K., Santos A.C., Nundy N., Jacoby E., Matthias D. Incremental costs of introducing jet injection technology for delivery of routine childhood vaccinations: comparative analysis from Brazil, India, and South Africa. Vaccine 2011, 29:969-975.
23. Goswami A., Plun-Favreau J., Nicoloyannis N., Sampath G., Siddiqui M.N., Zinsou J.A. The real cost of rabies post-exposure treatments. Vaccine 2005, 23(23):2970-2976.
24. Hampson K., Cleaveland S., Briggs D. Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries. PLoS Negl Trop Dis 2011, 5(3):e982.
25. Brown D., Featherstone J.J., Fooks A.R., Gettner S., Lloyd E., Schweiger M. Intradermal pre-exposure rabies vaccine elicits long lasting immunity. Vaccine 2008, 26(31):3909-3912.
26. WHO Assessing the programmatic suitability of vaccine candidates for WHO prequalification 2012, Available at:. http://www.who.int/immunization_standards/vaccine_quality/who_pspq_criteria.pdf.
27. Picot V. Intradermal immunization: an alternative route for vaccine administration. Articles as per sessions meeting report. Vaccine 2008, 26(Suppl. 9):S1-S5.
28. Lee B.Y., Norman B.A., Assi T.M., Chen S.I., Bailey R.R., Rajgopal J., et al. Single versus multi-dose vaccine vials: an economic computational model. Vaccine 2010, 28(32):5292-5300.
29. Arnou R., Frank M., Hagel T., Prebet A. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany. Adv Ther 2011, 28(7):555-565.
30. Chen X., Fernando G.J., Crichton M.L., Flaim C., Yukiko S.R., Fairmaid E.J., et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release 2011 Jun 30, 152(3):349-355.
31. Sudarshan M.K., Mahendra B.J., Ashwath Narayana D.H., Ananda Giri M.S. A guide to intradermal rabies vaccination 2006, Kempegowda Institute of Medical Sciences, Bangalore, India.